Rep. Gilbert Ray Cisneros, Jr. sold Viatris (VTRS)
Rep. Gilbert Ray Cisneros, Jr. (D-CA-31) · $1K–$15K · traded Mar 31, 2025
- Transaction
- Sold (partial)
- Amount
- $1K–$15K
- Owner
- Not stated
- Traded
- Mar 31, 2025
- Disclosed
- Apr 7, 2025
- Days to disclose
- 7
- Asset type
- Stock
- As filed
- Viatris Inc. - Common Stock
- Industry
- Drug Manufacturers - Specialty & Generic · Healthcare
Other trades in this filing
All of Cisneros's trades →- Apr 7, 2025$15K–$50K
$15K–$50K · Traded Apr 1, 2025 · disclosed Apr 7, 2025
- Apr 7, 2025$15K–$50K
$15K–$50K · Traded Apr 1, 2025 · disclosed Apr 7, 2025
- Apr 7, 2025$1K–$15K
Sold (partial) W. R. Berkley WRB
$1K–$15K · Traded Apr 1, 2025 · disclosed Apr 7, 2025
- Apr 7, 2025$15K–$50K
$15K–$50K · Traded Mar 31, 2025 · disclosed Apr 7, 2025
- Apr 7, 2025$1K–$15K
$1K–$15K · Traded Mar 31, 2025 · disclosed Apr 7, 2025
- Apr 7, 2025$15K–$50K
Sold (partial) Merck & Co. MRK
$15K–$50K · Traded Mar 31, 2025 · disclosed Apr 7, 2025
- Apr 7, 2025$1K–$15K
$1K–$15K · Traded Mar 31, 2025 · disclosed Apr 7, 2025
Committee overlap: Armed ServicesGot $7K from the company’s PAC - Apr 7, 2025$1K–$15K
$1K–$15K · Traded Mar 31, 2025 · disclosed Apr 7, 2025
- Apr 7, 2025$1K–$15K
Sold (partial) Labcorp Holdings LH
$1K–$15K · Traded Mar 31, 2025 · disclosed Apr 7, 2025
- Apr 7, 2025$1K–$15K
$1K–$15K · Traded Mar 31, 2025 · disclosed Apr 7, 2025
- Apr 7, 2025$1K–$15K
$1K–$15K · Traded Mar 31, 2025 · disclosed Apr 7, 2025
- Apr 7, 2025$15K–$50K
$15K–$50K · Traded Mar 31, 2025 · disclosed Apr 7, 2025
- Apr 7, 2025$1K–$15K
Bought Palantir Technologies PLTR
$1K–$15K · Traded Mar 31, 2025 · disclosed Apr 7, 2025
- Apr 7, 2025$1K–$15K
Sold (partial) Wynn Resorts, Limited WYNN
$1K–$15K · Traded Mar 31, 2025 · disclosed Apr 7, 2025
- Apr 7, 2025$1K–$15K
$1K–$15K · Traded Mar 31, 2025 · disclosed Apr 7, 2025
- Apr 7, 2025$15K–$50K
$15K–$50K · Traded Mar 31, 2025 · disclosed Apr 7, 2025
- Apr 7, 2025$15K–$50K
$15K–$50K · Traded Mar 31, 2025 · disclosed Apr 7, 2025
- Apr 7, 2025$1M–$5M
Bought Audent Hospitality Real Estate Fund I L.P.
$1M–$5M · Traded Mar 26, 2025 · disclosed Apr 7, 2025
- Apr 7, 2025$250K–$500K
Bought Antioch, CA, Unified School District GO Bonds
$250K–$500K · Traded Mar 24, 2025 · disclosed Apr 7, 2025
- Apr 7, 2025$1K–$15K
Sold (partial) Intra-Cellular Therapies ITCI
$1K–$15K · Traded Mar 24, 2025 · disclosed Apr 7, 2025
Recent Congress trades in VTRS
- Dec 15, 2025$1K–$15K
Rep. Gilbert Ray Cisneros, Jr. (D-CA-31)
$1K–$15K · Traded Nov 18, 2025 · disclosed Dec 15, 2025
- May 8, 2025$1K–$15K
Rep. Robert P. Bresnahan, Jr. (R-PA-8)
$1K–$15K · Traded Apr 8, 2025 · disclosed May 8, 2025
- Mar 27, 2025$1K–$15K
Rep. Robert P. Bresnahan, Jr. (R-PA-8)
$1K–$15K · Traded Feb 25, 2025 · disclosed Mar 27, 2025
- Dec 5, 2024$1K–$15K
- May 19, 2023$1K–$15K
Rep. Daniel S. Goldman (D-NY-10)
$1K–$15K · Traded Apr 10, 2023 · disclosed May 19, 2023
- Apr 17, 2023$1K–$15K
Rep. Daniel S. Goldman (D-NY-10)
$1K–$15K · Traded Mar 6, 2023 · disclosed Apr 17, 2023
- Feb 24, 2023$1K–$15K
Rep. Daniel S. Goldman (D-NY-10)
$1K–$15K · Traded Jan 31, 2023 · disclosed Feb 24, 2023
- Sep 15, 2022$1K–$15K
Sen. Tommy Tuberville (R-AL)
$1K–$15K · Traded Aug 1, 2022 · disclosed Sep 15, 2022
Company context for VTRS
Recent records for the company. These may have been published before or after this trade; compare the dates before drawing a connection.
VTRS: third_quarter 2026 lobbying report
S. 891, the Bipartisan Health Care Act Part D Formulary Design and Generic Drug Tiering HR 4132 / S.2027 - Prescription Information Modernization Act Medicaid Generics Penalty Implementation of the Inflation Reduction Act Drug Shortages S. 2658, The Medication Affordability and Patent Integrity Act IP Issues related to generic medicines Patent Settlements Trade issues related to generic medicines Pharmaceutical supply chain S.3778: Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings Act S.3841: Last Sale Valuation Act Policy related to corporate
Public: Oct 20, 2026, 8:43 PM EDTOriginal source ↗VTRS: third_quarter 2026 lobbying report
Policy and oversight related to the generic pharmaceutical industry. Issues related to drug pricing. Issues related to FDA generic drug approval process. General issues related to Agriculture Appropriations and National Defense Authorization Act (S. 1071). Trade issues related to generic medicines.
Public: Oct 19, 2026, 4:20 PM EDTOriginal source ↗VTRS: third_quarter 2026 lobbying report
S. 1302 - Increasing Transparency in Generic Drug Applications Act; Supply Chain Issues; E-labeling; Inflation Reduction Act Implementation; Improving Generic Drug Access; Drug Shortages; Medicaid Generics Penalty.
Public: Oct 7, 2026, 6:43 AM EDTOriginal source ↗
From a periodic transaction report filed under the STOCK Act. Amounts are the ranges members report. Nothing here is investment advice.